Hyundai Bio Receives IRB Approval for Phase 2 Clinical Trial of Oral COVID-19 Treatment 'CP-COV03'

원본보기 아이콘

[Asia Economy Reporter Lee Chun-hee] Hyundai Bio announced on the 5th that the phase 2 clinical trial plan for 'CP-COV03,' an oral antiviral drug for COVID-19 under development, received approval on the 4th from the Institutional Review Board (IRB) of Bestian Hospital, the clinical trial institution.

A Hyundai Bio official stated, "In cooperation with the clinical contract research organization DTNCRO, we will recruit patients to participate in the clinical trial and proceed with the medication process as quickly as possible."

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.